Similar articles

• Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

  Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N. Socinski MA, et al. J Clin Oncol. 2009 Oct 1;27(28):4787-92. doi: 10.1200/JCO.2009.23.1548. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720897 Clinical Trial.
• Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.

  Reck M, Thatcher N, Smit EF, Lorigan P, Szutowicz-Zielinska E, Liepa AM, Winfree KB, Peterson P, Guba SC, Socinski MA. Reck M, et al. Lung Cancer. 2012 Dec;78(3):276-81. doi: 10.1016/j.lungcan.2012.09.002. Epub 2012 Oct 6. Lung Cancer. 2012. PMID: 23043970
• Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.

  Smit EF, Socinski MA, Mullaney BP, Myrand SP, Scagliotti GV, Lorigan P, Reck M, Ciuleanu T, von Pawel J, Karaseva NA, Szczesna A, Ohannesian D, Powell E, Hozak RR, Hong S, Guba SC, Thatcher N. Smit EF, et al. Ann Oncol. 2012 Jul;23(7):1723-9. doi: 10.1093/annonc/mdr563. Epub 2011 Dec 19. Ann Oncol. 2012. PMID: 22186609
• Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.

  Ferraldeschi R, Thatcher N, Lorigan P. Ferraldeschi R, et al. Expert Rev Anticancer Ther. 2007 May;7(5):635-40. doi: 10.1586/14737140.7.5.635. Expert Rev Anticancer Ther. 2007. PMID: 17492928 Review.
• [Lung cancer].

  Ono A, Yamamoto N. Ono A, et al. Gan To Kagaku Ryoho. 2007 Mar;34(3):367-73. Gan To Kagaku Ryoho. 2007. PMID: 17353626 Review. Japanese.